SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

PharmaCyte Biotech, Inc. 
 CA
  SEC # 1157075


        
    Click to view...      Registrant      About      Filings      Files      Relationships      Names    
  Topics  
    Web       

204  Topics
Topic emoji
 within the 

Show:   Most-Recent Document   All Documents   And:   Exhibits  

 As Of  Filing  Doc.  Page    Title Docs.
  In ascending order
3/27/24DEF 14A1Advisory Vote on Approval of Executive Compensation as Disclosed in This Proxy Statement
7/31/23DEF 14A1Appendix A -- Text of Amendment to Articles of Incorporation to Increase Authorized Shares
1Authorized Share Proposal
7/31/2310-K1Business
9/21/23S-3/A1Capitalization
3/27/24DEF 14A1Certain Relationships and Related Person Transactions
7/31/2310-K1Certain Relationships and Related Transactions, and Director Independence
1Changes in and Disagreements With Accountants on Accounting and Financial Disclosures
3/27/24DEF 14A1Code of Conduct and Ethics
3/18/2410-Q1Condensed Consolidated Balance Sheets as of January 31, 2024 and April 30, 2023 (Unaudited)
9/18/2310-Q1Condensed Consolidated Balance Sheets as of July 31, 2023, and April 30, 2023 (Unaudited)
12/15/2310-Q1Condensed Consolidated Balance Sheets as of October 31, 2023 and April 30, 2023 (Unaudited)
3/18/2410-Q1Condensed Consolidated Financial Statements (Unaudited)
1Condensed Consolidated Statements of Cash Flows for the Nine Months Ended January 31, 2024 and 2023 (Unaudited)
12/15/2310-Q1Condensed Consolidated Statements of Cash Flows for the Six Months Ended October 31, 2023 and 2022 (Unaudited)
9/18/2310-Q1Condensed Consolidated Statements of Cash Flows for the Three Months Ended July 31, 2023, and 2022 (Unaudited)
12/15/2310-Q1Condensed Consolidated Statements of Comprehensive Income (Loss) for the Three and Six Months Ended October 31, 2023 and 2022 (Unaudited)
3/18/2410-Q1Condensed Consolidated Statements of Comprehensive Loss for the Three and Nine Months Ended January 31, 2024 and 2023 (Unaudited)
9/18/2310-Q1Condensed Consolidated Statements of Comprehensive Loss for the Three Months Ended July 31, 2023, and 2022 (Unaudited)
3/18/2410-Q1Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity for the Nine Months Ended January 31, 2024 and 2023 (Unaudited)
12/15/2310-Q1Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity for the Six Months Ended October 31, 2023 and 2022 (Unaudited)
9/18/2310-Q1Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity for the Three Months Ended July 31, 2023, and 2022 (Unaudited)
3/18/2410-Q1Condensed Consolidated Statements of Operations for the Three and Nine Months Ended January 31, 2024 and 2023 (Unaudited)
12/15/2310-Q1Condensed Consolidated Statements of Operations for the Three and Six Months Ended October 31, 2023 and 2022 (Unaudited)
9/18/2310-Q1Condensed Consolidated Statements of Operations for the Three Months Ended July 31, 2023, and 2022 (Unaudited)
7/31/2310-K1Consolidated Balance Sheets as of April 30, 2023, and 2022
1Consolidated Statements of Cash Flows for the Years Ended April 30, 2023, and 2022
1Consolidated Statements of Comprehensive Loss for the Years Ended April 30, 2023, and 2023
1Consolidated Statements of Operations for the Years Ended April 30, 2023, and 2022
1Consolidated Statements of Stockholders' Equity for the Years Ended April 30, 2023, and 2022
3/18/2410-Q1Controls and Procedures
1Defaults Upon Senior Securities
7/31/2310-K1Directors, Executive Officers and Corporate Governance
1Disclosure Regarding Foreign Jurisdictions That Prevent Inspections
3/27/24DEF 14A1Election of Directors
1Equity Compensation Plan Information
7/31/2310-K1Executive Compensation
3/27/24DEF 14A1Executive Officer and Director Compensation
3/18/2410-Q1Exhibits
9/21/23S-3/A1Experts
3/18/2410-Q1Financial Information
7/31/2310-K1Financial Statement Schedule II -- Valuation and Qualifying Accounts
1Financial Statements and Supplementary Data
1Form 10-K Summary
3/27/24DEF 14A1Important Information About the Annual Meeting and Voting
7/31/23DEF 14A1Important Information About the Special Meeting and Voting
9/21/23S-3/A1Information Incorporated by Reference
7/31/23DEF 14A1Issuance Proposal
9/21/23S-3/A1Legal Matters
3/18/2410-Q1Legal Proceedings
3/27/24DEF 14A1Management and Corporate Governance
3/18/2410-Q1Management's Discussion and Analysis of Financial Condition and Results of Operations
7/31/2310-K1Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
3/18/2410-Q1Mine Safety Disclosures
1Notes to Condensed Consolidated Financial Statements (Unaudited)
7/31/2310-K1Notes to Consolidated Financial Statements
9/21/23S-3/A1Offering, The
3/18/2410-Q1Other Information
3/27/24DEF 14A1Other Matters
1Pay Versus Performance
9/21/23S-3/A1Plan of Distribution
1Powers of Attorney
7/31/2310-K1Principal Accountant Fees and Services
1Properties
3/27/24DEF 14A1Proposal No. 1 -- Election of Directors
7/31/23DEF 14A1Proposal No. 1 -- Issuance Proposal
1Proposal No. 2 -- Authorized Share Proposal
3/27/24DEF 14A1Proposal No. 2 -- Ratification of Selection of Independent Registered Public Accounting Firm
1Proposal No. 3 -- Advisory Vote on Approval of Executive Compensation as Disclosed in This Proxy Statement
9/21/23S-3/A1Prospectus Summary
3/18/2410-Q1Quantitative and Qualitative Disclosures About Market Risk
3/27/24DEF 14A1Ratification of Selection of Independent Registered Public Accounting Firm
7/31/2310-K1Recommendation must also be accompanied by the following information concerning the proposed nominee, The
3/27/24DEF 14A1Report of Audit Committee
7/31/2310-K1Report of Independent Registered Public Accounting Firm
1Reserved
3/18/2410-Q1Risk Factors
3/27/24DEF 14A1Security Ownership of Certain Beneficial Owners and Management
7/31/2310-K1Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
9/21/23S-3/A1Selling Stockholders
3/18/2410-Q1Signatures
9/21/23S-3/A1Special Note Regarding Forward-Looking Statements
3/27/24DEF 14A1Stockholder Proposals and Nominations for Director
1Table of Contents
7/31/23DEF 14A1Text of Amendment to Articles of Incorporation to Increase Authorized Shares
9/21/23S-3/A1The Offering
7/31/2310-K1The recommendation must also be accompanied by the following information concerning the proposed nominee
3/18/2410-Q1Unregistered Sales of Equity Securities and Use of Proceeds
7/31/2310-K1Unresolved Staff Comments
9/21/23S-3/A1Use of Proceeds
7/31/2310-K1Valuation and Qualifying Accounts
9/21/23S-3/A1Where You Can Find Additional Information
124.1

Top

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Thu., May 16, 12:31:31.2am ET